(Health-NewsWire.Net, April 05, 2016 ) Diabetes, often referred to as diabetes mellitus, results in high blood glucose levels. Depending on the cause of development, it can be divided into three types: Type 1 diabetes (or insulin-dependent diabetes mellitus): The pancreas do not produce the required amount of insulin in the body, leading to high blood glucose levels. Type 2 diabetes (non-insulin-dependent diabetes mellitus): In this condition, though the body produces the required amount of insulin, the cells do not respond to it. This results in a high glucose level in the body. Gestational diabetes: This condition occurs in pregnant women without any history of diabetes. Type 1 diabetes is an autoimmune disorder characterized by high blood glucose levels. In this condition, the immune system is activated against insulin-producing cells. This condition hampers the bodys ability to produce insulin and disrupts blood glucose homeostasis. Type 1 diabetes differs from a more prevalent form of diabetes mellitus, type 2 diabetes, wherein the insulin is produced inside the body. Type 1 diabetes accounts for only 5%-15% of the total diabetes cases. As the disease is more prevalent among children and adolescents aged 0-15 years, it was earlier known as juvenile diabetes. Type 1 diabetes management relies on providing symptomatic relief and improving the quality of life of people.
To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=685165
Market analysts forecast the global type 1 diabetes drugs market to grow at a CAGR of 8.05% during the period 2016-2020.
Covered in this report The report covers the present scenario and the growth prospects of the global type 1 diabetes drugs market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded drugs and biosimilars used to treat and prevent type 1 diabetes.
The market is divided into the following segments based on geography: Americas APAC EMEA
New report, Global Type 1 Diabetes Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors Eli Lilly and Company Novo Nordisk A/S Sanofi SA
Other prominent vendors Adocia Astellas Pharma AstraZeneca Baxalta BHV Pharma Biocon Biodel Boehringer Ingelheim CureDM Dance Biopharm Diamyd Therapeutics AB Diasome Pharmaceuticals DiaVac Exsulin Gan & Lee Pharmaceuticals Generex Biotechnology GlaxoSmithKline ILTOO Pharma Intrexon Islet Sciences Kamada Kotobuki Pharmaceutical Lexicon Pharmaceuticals Living Cell Technologie MacroGenics MannKind Pharmaceuticals Merck Merrion Pharmaceutical Oramed Pharmaceuticals Osiris Therapeutics Perle Biosciences Pfizer REGiMMUNE Strongbridge Biopharma Toleranzia Tolerio Xeris Pharmaceuticals XOMA
Market driver Increase in prevalence of type 1 diabetes For a full, detailed list, view our report
Market challenge Poor storage conditions and distribution policies for insulin For a full, detailed list, view our report
Market trend Awareness programs and initiatives For a full, detailed list, view our report
Key questions answered in this report What will the market size be in 2020 and what will the growth rate be? What are the key market trends? What is driving this market? What are the challenges to market growth? Who are the key vendors in this market space? What are the market opportunities and threats faced by the key vendors? What are the strengths and weaknesses of the key vendors?
Browse Detail Report With TOC @ http://www.researchmoz.us/global-type-1-diabetes-market-2016-2020-report.html
Table Of Content
PART 01: Executive summary Highlights PART 02: Scope of the report Market overview Top-vendor offerings PART 03: Market research methodology Research methodology Economic indicators PART 04: Introduction Key market highlights Key buying criteria PART 05: Disease overview Introduction Risk factors Diagnosis Management Epidemiology Economic burden PART 06: Insulin: An overview Product portfolio Global human insulin market PART 07: Pipeline analysis Faster-acting insulin aspart (NN1218) Farxiga/Forxiga SAR342434 NN9211 LY2605541 Sotagliflozin MK-1293 PRL001 Otelixizumab PART 08: Reimbursement scenario in US PART 09: Market landscape Global diabetes drugs market Global type 1 diabetes drugs market Five forces analysis PART 10: Market segmentation by drug class Insulin Others PART 11: Geographical segmentation Type 1 diabetes drugs market in Americas Type 1 diabetes drugs market in EMEA Type 1 diabetes drugs market in APAC PART 12: Market drivers Increase in prevalence of type 1 diabetes Advances in insulin delivery technology Rise in price of insulin drugs Stringent regulatory conditions for biosimilar drugs Promising drug pipeline PART 13: Impact of drivers PART 14: Market challenges Side effects of current therapies Fierce market competition Poor storage conditions and distribution policies for insulin Gap in nation-level diabetes management plans Rising concerns in scientific community PART 15: Impact of drivers and challenges PART 16: Market trends Development of drugs with novel mechanisms Awareness programs and initiatives Focus on emerging markets Increase in academia-industry collaboration PART 17: Vendor landscape Competitive scenario Market analysis 2015 Novo Nordisk Sanofi Eli Lilly Other prominent vendors PART 18: Appendix List of abbreviations
Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=685165
About ResearchMoz
ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.
For More Information Kindly Contact:
ResearchMoz Mr. Nachiket Ghumare, Tel: +1-518-621-2074 USA-Canada Toll Free: 866-997-4948 Email: sales@researchmoz.us
Browse Our Latest Press Releases @ http://www.researchmoz.us/pressrelease
Researchmoz Global Pvt.Ltd
Researchmoz
+1-518-621-2074
sales@researchmoz.us
Source: EmailWire.Com
|